Final data from the ECWM-1 (NCT01788020) showed that adding bortezomib to dexamethasone, rituximab and cyclophosphamide (DRC) does not convey a survival benefit for patients with Waldenström ...
Longer-term results from the BENEFIT trial show sustained minimal residual disease negativity in newly diagnosed, ...
Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomography–Directed Therapy for Early-Stage Hodgkin Lymphoma ...
LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today the availability in the United States of Bortezomib for Injection. Fresenius Kabi Bortezomib for Injection is available as a single ...
TARRYTOWN, N.Y., May 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced initial results from two cohorts of the Phase 1b LINKER-MM2 trial evaluating linvoseltamab in ...
Please provide your email address to receive an email when new articles are posted on . Healio spoke with Chakra Chaulagain, MD, about a retrospective observational study on prescribing patterns and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback